Liminatus Pharma Q1 Net Loss Widens to $1.12M, EPS $(0.03), Amid Ongoing Going Concern Doubts
LIMN sits 16% above its 52-week low of $0.159 on light trading volume (0.2× avg).
Summary
Liminatus Pharma reported a significant widening of its net loss for the first quarter of 2026, reaching $1.12 million, with diluted EPS of $(0.03). This compares to a net loss of $0.33 million and diluted EPS of $(0.02) in the prior year's quarter, indicating a substantial deterioration in financial performance. This negative update comes as the pre-clinical biotech company was already facing significant doubt about its ability to continue as a going concern, as highlighted in its last 10-K filing. The increased losses, driven by R&D and public-company operational costs, are highly material for a company with a very small market capitalization, consuming a portion of the $3.44 million raised in a February 2026 offering. Traders will view this as a reinforcement of the company's precarious financial position and will be watching for further updates on its ability to secure additional funding or achieve clinical milestones.
At the time of this announcement, LIMN was trading at $0.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1M. The 52-week trading range was $0.16 to $33.66. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.